Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/45088
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWarawan Eiamphungpornen_US
dc.contributor.authorNalini Schaduangraten_US
dc.contributor.authorAijaz Ahmad Maliken_US
dc.contributor.authorChanin Nantasenamaten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2019-08-23T10:29:44Z-
dc.date.available2019-08-23T10:29:44Z-
dc.date.issued2018-08-01en_US
dc.identifier.citationInternational Journal of Molecular Sciences. Vol.19, No.8 (2018)en_US
dc.identifier.issn14220067en_US
dc.identifier.issn16616596en_US
dc.identifier.other2-s2.0-85052093400en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052093400&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/45088-
dc.description.abstract© 2018 by the authors. Licensee MDPI, Basel, Switzerland. β-Lactams are the most widely used and effective antibiotics for the treatment of infectious diseases. Unfortunately, bacteria have developed several mechanisms to combat these therapeutic agents. One of the major resistance mechanisms involves the production of β-lactamase that hydrolyzes the β-lactam ring thereby inactivating the drug. To overcome this threat, the small molecule β-lactamase inhibitors (e.g., clavulanic acid, sulbactam and tazobactam) have been used in combination with β-lactams for treatment. However, the bacterial resistance to this kind of combination therapy has evolved recently. Therefore, multiple attempts have been made to discover and develop novel broad-spectrum β-lactamase inhibitors that sufficiently work against β-lactamase producing bacteria. β-lactamase inhibitory proteins (BLIPs) (e.g., BLIP, BLIP-I and BLIP-II) are potential inhibitors that have been found from soil bacterium Streptomyces spp. BLIPs bind and inhibit a wide range of class A β-lactamases from a diverse set of Gram-positive and Gram-negative bacteria, including TEM-1, PC1, SME-1, SHV-1 and KPC-2. To the best of our knowledge, this article represents the first systematic review on β-lactamase inhibitors with a particular focus on BLIPs and their inherent properties that favorably position them as a source of biologically-inspired drugs to combat antimicrobial resistance. Furthermore, an extensive compilation of binding data from β-lactamase–BLIP interaction studies is presented herein. Such information help to provide key insights into the origin of interaction that may be useful for rationally guiding future drug design efforts.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85052093400&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectChemical Engineeringen_US
dc.subjectChemistryen_US
dc.subjectComputer Scienceen_US
dc.titleTackling the antibiotic resistance caused by class a β-lactamases through the use of β-lactamase inhibitory proteinen_US
dc.typeReviewen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.3390/ijms19082222en_US
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.